SAN MATEO, Calif. And VENLO, The Netherlands, Jan. 5, 2023 /PRNewswire/ -- Helix, the leading population genomics and viral surveillance company in the nation, announced today a global strategic partnership with QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), the leading global provider of Sample to Insight solutions, to jointly develop companion diagnostics for hereditary diseases. As part of the collaboration, Helix will leverage the Helix® Laboratory Platform to develop companion diagnostics in the U.S., and QIAGEN will use the QIASeq Human Exome Kits in the rest of world.
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
